|
Apr 16
|
Weekly Picks: 🧠Alphabet’s AI edge, CSL’s pricing power, and a chip underdog
|
|
Apr 13
|
Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
|
|
Feb 20
|
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
|
|
Jan 10
|
Is CSL Limited (ASX:CSL) Trading At A 30% Discount?
|